Can p53, Ki-67 and bcl-2 predict biochemical failure after radical prostatectomy

Indian Journal of Urology

Volumn 26, Issue 2, 2010, Pages 206-212

  Baseskioglu, B ^a   Akdogan, B ^a   Baydar, D E ^a   Ozen, H ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Bcl 2; ki 67; microarray; p53; prostate cancer

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BASAL CELL; CANCER STAGING; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUE MICROARRAY; TUMOR CELL;

EID: 77954974038     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.65390     Document Type: Article

References (24)

1. Catalona WJ. Surgical management of prostate cancer: Contemporary results with anatomic radical prostatectomy. Cancer 1995;75:1903.
2. Bauer JJ, Sesterhehn I, Mostofi F, McLeod DG, Moul JW. Elevated levels of apopitosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996;156:1511.
3. Brooks JD, Bova GS, Ewing CM. An uncertain role for p53 gene alterations in human prostate cancer. Cancer Res 1996;56:3814-3822
4. D'Amico AV. Combined modality staging for localized adenocarcinoma of prostate. Oncology (Williston Park) 2001;15:1049-59; discussion 1060-2, 1064-5, 1069-70, 1073-1075
5. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-526
6. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-456
7. Finlay C, Hinds P, Tan T, Eliyahu D, Oren M, Levine A. Activating mutations for transformation by p53 produce a gene product that forms a hsc7O-p53 complex with an altered half-life. Moll Cell Biol 1988;8:531-539
8. Mirchandini D, Zeng J, Miller GJ, Cote DK, Burman P. Heterogeneity in intratumour distribution of p53 mutations in human prostate cancer. Am J Pathol 1995;147:92.
9. Schlomm T, Iwers L, Kirstein P, Jessen B, Köllermann J, Minner S, et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 2008;21:1371-1378
10. Byrne R, Horne W, Robinson M, Bishop R, Hamdy F. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. BJU Int 1997;79:190-195
11. Nariculam J, Freeman A, Bott S, Munson P, Cable N, Brookman-Amissah N, et al. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: The expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors. Asian J Androl 2009;11:109-118
12. Stackhouse G, Sesterhehn I, Bauer J, Mostofi FK, Moul JW. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 1999;162:2040.
13. Korsmeyer SJ. Bcl- 2 initiates a new category of oncogenes: Regulators of cell death. Blood 1992;80:879-886
14. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, et al. Expression of the protooncogene Bcl- 2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-6944
15. Colombel M, Symmans F, Gil SO, Chopin D, Benson M, Olsson CA, et al. Detection of the apoptosis-suppressing oncoprotein Bcl- 2 in hormonerefractory human prostate cancers. Am J Pathol 1993;143:390-400.
16. Takahiro I, Takehiko S, Taizou S, Toru Y, Tomomi Y, Naoko K, et al. Androgen receptor, Ki-67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 2005;66:332-337
17. Levine AJ, Momand J, Finlay A. The p53 tumour supressor gene. Nature 1991;351:453.
18. Visakorpi T. Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma. J Pathol 1992;168:7-13.
19. Harper ME, Glynne JE, Goddard L, Wilson DW, Matenhelia SS, Conn IG, et al. Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters. Prostate 1992;20:243-253
20. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, et al. Ki- 67 labeling index: An independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996;178:437-441
21. Gali S, Gaboardi F, Rozzola A, Ferrari A. Immunohistochemical expression of bcl-2, p53, ki-67 and choromograms in prostatic carcinoma: Correlation with stage and grade. J Urol 1995;153:483.
22. Catalona WJ, Smith DS. Five year tumour recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152:1837.
23. Huakaas S, Halversen O, Hostmark J, Akslen L. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer? BJU 2006;97:51.
24. Kupelian P, Katcher J, Levin H, Zippe C, Klein E. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996;48:249-260